Jeonjinbio Balance Sheet Health
Financial Health criteria checks 2/6
Jeonjinbio has a total shareholder equity of ₩6.2B and total debt of ₩5.3B, which brings its debt-to-equity ratio to 85.4%. Its total assets and total liabilities are ₩17.7B and ₩11.5B respectively.
Key information
85.4%
Debt to equity ratio
₩5.31b
Debt
Interest coverage ratio | n/a |
Cash | ₩1.69b |
Equity | ₩6.22b |
Total liabilities | ₩11.48b |
Total assets | ₩17.70b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A110020's short term assets (₩7.8B) do not cover its short term liabilities (₩11.2B).
Long Term Liabilities: A110020's short term assets (₩7.8B) exceed its long term liabilities (₩271.3M).
Debt to Equity History and Analysis
Debt Level: A110020's net debt to equity ratio (58.1%) is considered high.
Reducing Debt: A110020's debt to equity ratio has increased from 57.1% to 85.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A110020 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A110020 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.6% each year